Skip to main content
. 2022 Jan 22;100(4):555–568. doi: 10.1007/s00109-022-02177-4

Fig. 3.

Fig. 3

Plasma levels of glutamate and metabolites in COVID-19 patients. Plasma levels of amino acids, proteolysis markers and amino acid synthesis substrates were analyzed in COVID-19 patients with low (< 15 pg/mL, light blue dots) and high (> 15 pg/mL, dark blue dots) IL-6 levels and control patients (grey dots) by targeted metabolomics. Data are expressed in µmol/L. Glutamine and its metabolites were identified as the pathway most downregulated in SARS-CoV-2 infection. *p < 0.05; **p < 0.01; ***p < 0.001 compared to control group